The State of Healthcare
if Trump Gets Reelected
Read the White Paper
Our latest white paper outlines how a hypothetical Trump reelection in November could impact healthcare. This brief is among the first and most comprehensive analyses to address the topic. Topics and priorities Douglas Hervey cover include:
- Drug Price Reforms and Rebate Cuts;
- Price Transparency;
- Interoperability and Information Sharing;
- Medicare Advantage;
- Value-Based Care;
- Surprise Medical Billing;
- Health Savings Accounts (HSAs);
- Health Reimbursement Accounts (HRAs);
- Medicaid Reforms;
- Association and Short-Term Health Plans;
- Individual Market Enrollment and Subsidies; and
- 340B Curbs.
Cicero Group does not endorse platforms or policies; nor does it endorse the healthcare positions covered in these briefs. Rather, Cicero Group highlights perspectives across the political spectrum to further educate and engage readers in key areas that could impact their families, businesses, and communities.
Douglas Hervey is a principal at Cicero Group with an emphasis in healthcare and life science services. Douglas most recently worked as a senior director for Leavitt Partners. As a senior director, Douglas enabled healthcare entities to more effectively aggregate data, automate research processes, and make sound growth-oriented strategic and investment decisions. He has worked on over 200 healthcare private equity investment deals, within 80 unique healthcare sub-segments, for over 40 investment funds.
Douglas earned his bachelor’s degree in international relations at Brigham Young University, after which he earned his juris doctorate from the University of Pittsburgh. Douglas also holds an MBA from Brigham Young University, where he was a Hawes Scholar.